RegeneRx Biopharmaceuticals, Inc. (RGRX)
USD 0.07
(0.0%)
USD 0.07
(0.0%)
| Breakdown | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -940.71 Thousand | -990.29 Thousand | -1 Million | -1.13 Million | -888.29 Thousand | -663.08 Thousand |
| Net Income | -1.72 Million | -1.59 Million | -1.52 Million | -1.4 Million | -1.99 Million | 286.48 Thousand |
| Depreciation & Amortization | - | - | - | 1418.00 | 2753.00 | 3048.00 |
| Deferred income taxes | - | - | - | - | - | -2 Million |
| Stock-based compensation | 511.86 Thousand | 397.81 Thousand | 332 Thousand | 269.74 Thousand | 276.12 Thousand | 271.37 Thousand |
| Change in working capital | 39.22 Thousand | 30.16 Thousand | 22.25 Thousand | -110.08 Thousand | 177.57 Thousand | 653.77 Thousand |
| Other non-cash items | 235.64 Thousand | 179.47 Thousand | 162.17 Thousand | 105.2 Thousand | 648.8 Thousand | 122.83 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 3921.00 | 1.79 Million | 794.91 Thousand | 1.54 Million | 943.84 Thousand | 75.29 Thousand |
| Debt repayment | -3921.00 | -234.00 | -550.8 Thousand | -1.29 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 1.75 Million | 241.91 Thousand | 240.62 Thousand | 943.84 Thousand | 75.29 Thousand |
| Other Financing Activities | 7842.00 | 35.15 Thousand | 1.1 Million | 2.59 Million | 943.84 Thousand | 75.29 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 170.00 | 24.31 Thousand | -4358.00 | -48.75 Thousand | 25.97 Thousand | -9234.00 |
| Inventory | - | - | - | - | - | - |
| Other working capital | 39.05 Thousand | 5853.00 | 26.61 Thousand | -61.32 Thousand | 151.6 Thousand | 663 Thousand |
| Cash at beginning of period | 1.23 Million | 427.89 Thousand | 639.91 Thousand | 237.26 Thousand | 181.7 Thousand | 769.49 Thousand |
| Cash at end of period | 290.89 Thousand | 1.23 Million | 427.89 Thousand | 639.91 Thousand | 237.26 Thousand | 181.7 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -940.71 Thousand | 803.71 Thousand | -212.01 Thousand | 402.65 Thousand | 55.55 Thousand | -587.78 Thousand |
| Free Cash Flow | -940.71 Thousand | -990.29 Thousand | -1 Million | -1.13 Million | -888.29 Thousand | -663.08 Thousand |
| Breakdown | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 FY | 2022 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | - | - | -385.2 Thousand | -390.9 Thousand | -1.72 Million | -366.5 Thousand |
| Depreciation & Amortization | - | - | - | - | - | - |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | 86.33 Thousand | 86.33 Thousand | 511.86 Thousand | 86.33 Thousand |
| Change in working capital | - | - | 51.42 Thousand | 57.65 Thousand | 39.22 Thousand | -7464.00 |
| Other non-cash items | - | - | 58.1 Thousand | 59.39 Thousand | 235.64 Thousand | 59.39 Thousand |
| Investing Cash Flow | - | - | - | - | - | - |
| Investments in PPE | - | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | - | 1812.00 | 4590.00 | 3921.00 | -552.00 |
| Debt repayment | - | - | -1812.00 | -4590.00 | -3921.00 | -552.00 |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | - | - | 3624.00 | 9180.00 | 7842.00 | - |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | -25.11 Thousand | 26.64 Thousand | 170.00 | -8275.00 |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | 76.53 Thousand | 31 Thousand | 39.05 Thousand | 811.00 |
| Cash at beginning of period | - | 101.55 Thousand | 290.89 Thousand | 478.4 Thousand | 1.23 Million | 706.64 Thousand |
| Cash at end of period | - | 101.55 Thousand | 101.55 Thousand | 290.89 Thousand | 290.89 Thousand | 478.4 Thousand |
| Capital Expenditure | - | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | - | -189.33 Thousand | -187.51 Thousand | -940.71 Thousand | -228.23 Thousand |
| Free Cash Flow | - | - | -189.33 Thousand | -187.51 Thousand | -940.71 Thousand | -228.23 Thousand |
3324
UTZ
2866
BIGBLOC
FESTI
PZAKY